Citations

Clear

371 citation(s) found for "Cho, B".

Shared decision‐making for patients with vaccine‐related concerns of blood transfusion: A single institution experience
Cho, David , Klompas, Allan M. , Petsch, Jamie L., Burt, Jen M., Kor, Daryl J. , Buskirk, Camille M. van , Warner, Matthew A. , Cho, David J , Gonzalez, Jessica A, van Buskirk, Camille M, Warner, Matthew A , Gonzalez, Jessica A., Burt, Jen M., Winters, Jeffrey L.

Mayo Clinic

Transfusion | October 24, 2024 | Volume: 64 | Issue: 12 | Pages: 2247-2251

10.1111/trf.18052 | PMID 39446607 Get It

AbstractBackgroundSome patients express concerns regarding receipt of allogeneic blood transfusions from donors potentially vaccinated against SARS‐CoV‐2 (COVID‐19). However, limited information exists about patients' expression of these concerns or how to address them during the blood transfusion consent process. In this study, we describe our experience of working collaboratively with patients with vaccine‐related transfusion concerns prior to elective surgery, summarizing treatment decisions and clinical outcomes.Study Design and MethodsThis observational descriptive study includes patients seen in our Bloodless Medicine and Surgery clinic between June 2022 and June 2024 for vaccine‐related transfusion concerns prior to elective surgery. A shared decision‐making framework was employed to foster conversation, share information, provide reassurance, reconcile conflict, and match preferences with available care options. Patient characteristics, treatment decisions, and surgical outcomes were reviewed and summarized.ResultsThirty‐five patients were included, with median (1st, 3rd quartile) age of 61 (53, 69) years. Cardiac surgery was the most common type of surgery (29%). Twelve patients (34%) were anemic preoperatively, and all received preoperative treatment. After discussion with a Bloodless Medicine specialist, 24 (68.6%) decided to consent to the use of all blood products, 5 (14.3%) accepted only red blood cells, and 6 (17.1%) declined all blood products. Among 28 patients undergoing surgery, only 4 (14%) received allogeneic transfusion perioperatively.ConclusionMany patients concerned about the vaccination status of blood donors may ultimately consent to allogeneic blood products after shared decision‐making with a Bloodless Medicine specialist, highlighting the importance of patient empowerment and collaborative care.
Endoscopic, Endonasal, Transsphenoidal, Transclival Approach for Resection of Odontoid Process: 2-Dimensional Operative Video
Zervos, Thomas M. , Cho, Steve S. , Samiappan, Sathish Prabu Sathyamangalam , Little, Andrew S. , Santarelli, Griffin D., Ronecker, Jennifer S., McClendon, Jamal, Sathyamangalam Samiappan, Sathish Prabu

Mayo Clinic

Operative Neurosurgery | September 9, 2024 | Volume: 28 | Issue: 1 | Pages: 132-132

10.1227/ons.0000000000001350 | PMID 39248517 Get It

Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Acharya, Sahaja , Allison, Jenna , Alva, Elizabeth, Arndt, Carola, Benedetti, Daniel J. , Church, Alanna J. , Davidoff, Andrew M. , Desai, Ami V. , DuBois, Steven G. , Fair, Douglas , Farinhas, Joaquim M. , Harrison, Douglas J. , Huang, Frederick S., Iskander, Paul, Kreissman, Susan G. , Macy, Margaret E. , Pashankar, Farzana , Pendyala, Praveen, Polites, Stephanie F. , Rabah, Raja , Shimada, Hiroyuki , Slatnick, Leonora R. , Sokol, Elizabeth , Twist, Clare J. , Vo, Kieuhoa T. , Watt, Tanya , Wolden, Suzanne, Zage, Peter E. , Schonfeld, Ryan, Hang, Lisa, Polites, Stephanie, Bagatell, Rochelle , Park, Julie R. , Aldrink, Jennifer H. , Brown, Erin G. , Cho, Steve K. , Na, Brian , Pinto, Navin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 413-433

10.6004/jnccn.2024.0040 | PMID 39151455 Get It

Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The information in these guidelines was developed by the NCCN Neuroblastoma Panel, a multidisciplinary group of representatives with expertise in neuroblastoma, consisting of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologists from NCCN Member Institutions. The evidence-based and consensus recommendations contained in the NCCN Guidelines are intended to guide clinicians in selecting the most appropriate treatments for their patients with this clinically heterogeneous disease.
Integrating Radiomics Features from CT Imaging to Enhance Prognostic Accuracy and Clinical Decision-Making in Resectable Gastric Cancer
Kim, Minkyu , Cho, Sangwuk, Hwang, Taehyun , Kim, Hwiyoung , Lim, Joon Seok , Cheong, Jae‐Ho

Mayo Clinic

No container title available | August 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4707753/v1 Get It

Abstract Background: For resectable gastric cancer, postoperative adjuvant chemotherapy remains the standard modality for preventing recurrence and improving survival. Although a previous study proposed a model for stratifying risk and determining the likelihood of chemotherapeutic benefit following surgery, this model requires molecular genomic analysis of tumour tissues and only uses unidimensional data. However, a recent study revealed that a multiomics approach reflects more compressive cancer characteristics, providing more precise prediction of treatment response. Recent advancements indicate that radiomics features are predictive biomarkers of treatment response. The present study investigated whether computed tomography (CT) image-based quantitative radiomics combined with genomics data can provide clinically actionable information for a more detailed stratification of cancer patients. Methods: This retrospective multicohort study included patients with advanced gastric cancer treated with surgery plus adjuvant chemotherapy or surgery alone. Two filters were used to extract 1,106 radiomics features from preoperative venous-phase CT images. Dimensional reduction was performed via Cox regression with the LASSO method, following which the coefficients were used to determine the Rad-score. The optimal cutoff point was determined via the Kaplan-Meier method and used to divide the cohort into high- and low-risk groups. The primary endpoints were the predictive and prognostic performance of the Rad-score and nomogram in terms of overall survival and the value of adding the Rad-score to genetic information. Findings: The optimal Rad-score (11·978379207) successfully stratified patients into low- and high risk groups. Improved survival was noted among patients defined to have a ‘poor prognosis’ with GZMB–, WARS–, and SFRP+ genetic test results and among high-risk patients based on the Rad-score when no adjuvant chemotherapy was provided. Interpretation: Our findings suggest that the Rad-score can be used to further stratify patients in the response group, preventing potentially ineffective treatment and unnecessary adverse events in those with advanced gastric cancer
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
Debban, Catherine L., Ambalavanan, Amirthagowri , Ghosh, Auyon , Buschur, Kristina L., Ma, Yanlin , George, Elizabeth , Pistenmaa, Carrie L. , Bertoni, Alain G. , Oelsner, Elizabeth C. , Moraes, Theo J. , Jacobs, David R. , Christenson, Stephanie A. , Bhatt, Surya P. , Simons, Elinor , Turvey, Stuart E. , Vameghestahbanati, Motahareh , Bourbeau, Jean , Tan, Wan C. , Gabriel, Stacey , Gupta, Namrata , Woodruff, Prescott G. , Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Hoffman, Eric A. , Barr, R. Graham, Duan, Qing , Smith, Benjamin M. , George, Elizabeth , Bertoni, Alain G , Oelsner, Elizabeth C , Michos, Erin D , Moraes, Theo J , Bhatt, Surya P , Turvey, Stuart E , Engert, James C , Kirby, Miranda , Tan, Wan C , Woodruff, Prescott G , Subbarao, Padmaja , Rich, Stephen S , Hoffman, Eric A , Cho, Michael H , Bossé, Yohan , Duan, Qingling , Manichaikul, Ani W , Ghosh, Auyon J , Jacobs, David R , Christenson, Stephanie A , Ambalavanan, Amirthagowri , Li, Zhonglin , Michos, Erin D. , Kaner, Robert J. , Rich, Stephen S. , Cho, Michael H. , Bossé, Yohan , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 27, 2024 | Volume: 210 | Issue: 12 | Pages: 1421-1431

10.1164/rccm.202401-0011oc | PMID 38935874 Get It

Abstract Rationale Dysanapsis refers to a mismatch between airway tree caliber and lung size arising early in life. Dysanapsis assessed by computed tomography (CT) is evident by early adulthood and associated with chronic obstructive pulmonary disease (COPD) risk later in life. Objectives By examining the genetic factors associated with CT-assessed dysanapsis, we aimed to elucidate its molecular underpinnings and physiological significance across the lifespan. Methods We performed a genome-wide association study of CT-assessed dysanapsis in 11,951 adults, including individuals from two population-based and two COPD-enriched studies. We applied colocalization analysis to integrate genome-wide association study and gene expression data from whole blood and lung. Genetic variants associated with dysanapsis were combined into a genetic risk score that was applied to examine association with lung function in children from a population-based birth cohort (n = 1,278) and adults from the UKBiobank (n = 369,157). Measurements and Main Results CT-assessed dysanapsis was associated with genetic variants from 21 independent signals in 19 gene regions, implicating HHIP (hedgehog interacting protein), DSP, and NPNT as potential molecular targets based on colocalization of their expression. A higher dysanapsis genetic risk score was associated with obstructive spirometry among 5-year-old children and among adults in the fifth, sixth, and seventh decades of life. Conclusions CT-assessed dysanapsis is associated with variation in genes previously implicated in lung development, and dysanapsis genetic risk is associated with obstructive lung function from early life through older adulthood. Dysanapsis may represent an endophenotype link between the genetic variations associated with lung function and COPD.
A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.
Lee, Jeeyun , Cho, Byoung Chul , Adjei, Alex A. , Campian, Jian , Zhao, Yujie , Seetharam, ­Mahesh , Yun, Nari, Lee, Woohyung Wayne, Lee, Woo-Sun, Park, Sosun, Seo, Bochan, Kim, Ryunhee, Lee, Jae‐Lyun , Lee, Jung-Yun , Wee, Wen , Shim, Byoung Yong , Park, Sujeong , Lee, Woosun, Kim, Jay, Jang, Myoung Ho , Cho, B

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2598-2598

10.1200/jco.2024.42.16_suppl.2598 Get It

2598 Background: GI-102 (CD80-IL2v3) is a novel immunocytokine designed to direct IL-2v3 to immune cells and tumor cells. IL-2v3 of GI-102 abolished affinity to IL-2Rα minimizing the impact of IL-2 on Treg cells. Preferential targeting of immune cells and further inhibition of CTLA-4 and PD-L1 via CD80 synergize with potent activity of IL-2v3, resulting in robust proliferation and activation of CD8+ T and NK cells. Here we report preliminary safety and efficacy data of GI-102 from a phase 1/2a trial in patients with metastatic solid tumors. Methods: NCT05824975 is an ongoing, dose escalation (3+3 design) and expansion study to evaluate safety, tolerability, PK, PD and anti-tumor activity of GI-102. Each dose level allows to enroll additional 7 patients to fully inform the safety, PK and PD at that dose level. GI-102 was administered intravenously every 3 weeks until disease progression or unacceptable toxicities. Disease was assessed every 6 weeks using RECIST v1.1. Results: As of 12 Jan 2024, 32 patients were treated in dose escalation: 8 at dose level 0.06 mg/kg, 10 at 0.12 mg/kg, 9 at 0.24 mg/kg and 5 at 0.45 mg/kg. Patients had received median of 3 [1-7] prior lines of therapy, including 25.0% (8/32) who had received ≥ 5 lines and 68.8% (22/32) had experienced immune checkpoint blockade (ICB). No dose-limiting toxicities (DLTs) were observed until the highest dose of 0.45 mg/kg Q3W. The most common treatment-related adverse events (TRAEs, ≥ 10%) were pyrexia [43.8%] and chills [34.4%]. 5 patients [15.6%] had ≥ Grade 3 TRAEs and no patient reported TRAEs leading to discontinuation of GI-102. In 23 patients (7 cutaneous melanoma, 4 non-small cell lung cancer, 3 ovarian cancer and others) who had at least 1 post-treatment tumor assessment, objective responses were observed in 17.4% (4/23). In patients with metastatic melanoma who previously experienced ICB, overall response rate (ORR) and disease control rate (DCR) was 42.9% (3/7) and 85.7% (6/7), respectively, including 3 confirmed partial responses (cPR). The median time to response (TTR) was 6 weeks and duration of response (DoR) was 6.0+, 2.4+ and 1.7+ month, respectively. In patients with metastatic ovarian cancer, ORR and DCR were 33.3% (1/3) and 66.7% (2/3), respectively, including 1 cPR [TTR of 6 weeks; DoR 1.9+ month]. Preliminary PK profile showed target-mediated drug disposition with a half-life of ~48 hours. 0.24 mg/kg of GI-102 resulted in a significant expansion of peripheral lymphocytes, CD8+ T cells (effector & memory) and NK cells, by 4.4 [2.1-9.6], 3.9 [2.0–5.7] and 20.4 [9.5–32.6]-fold change from baseline, respectively. There was no meaningful increase in Treg cells. Conclusions: GI-102 was well tolerated up to dose of 0.45 mg/kg Q3W with meaningful monotherapy activity, regardless of previous ICB experience, in patients who failed on standard of care. The dose-escalation is currently ongoing to identify RP2D. Clinical trial information: NCT05824975 .
Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.
Federman, Noah , Reichardt, Peter , Attia, Steven , Lim, Allison , Amoruccio, Vincent, Cho, Sunny, Kasper, Bernd , Lim, Allison, Cho, Sunny, Riedel, Richard F.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11558-11558

10.1200/jco.2024.42.16_suppl.11558 Get It

11558 Background: Nirogacestat (niro) is a targeted and selective gamma secretase inhibitor approved in the US for adults with progressing desmoid tumors (DT). In the phase 3 DeFi study, niro demonstrated significant improvement vs placebo (pbo) in progression-free survival (PFS: HR, 0.29 [95% CI: 0.15-0.55]; P<.001), objective response rate (ORR: 41% vs 8%; P<.001); and patient-reported outcomes (PROs) of pain, DT-specific symptom burden, physical and role functioning, and overall quality of life ( P≤.01, all). DT are driven by Wnt/β-catenin signaling pathway alterations and about 10-20% of DT are associated with mutations in the APC tumor suppressor gene, which may confer more aggressive DT behavior. Because patients with APC mutations may do worse, regardless of specific therapy, a post hoc analysis was conducted to assess effects of niro in patients with progressing DT and APC mutations. Methods: DeFi was a global, double-blind study that evaluated the efficacy, safety, and tolerability of niro in adults with progressing DT. Patients were randomized to oral niro (150 mg) or pbo twice-daily in continuous 28-day cycles. Descriptive post hoc analyses were conducted to assess effects of niro in patients with somatic and/or germline APC mutations. Results: Among 29 patients in DeFi with APC mutations (niro=13; pbo=16), 19 (66%) were female, 16 (55%) were aged ≤30 years, and 22 (76%) were refractory to prior treatment (with a median of 3 prior lines of treatment). In patients with APC mutation, PFS was improved with niro vs pbo (HR, 0.21 [95% CI: 0.05-1.00], P=.016). Confirmed ORR was 38% (5/13) for niro vs 13% (2/16) for pbo. Niro-treated patients also had greater reduction in median best percent change from baseline compared with pbo-treated patients in target tumor size (-29.5 vs +2.2), volumetric MRI (-71.0 vs +5.4), and T2 hyperintensity (-74.1 vs -21.0). Across all PROs assessed — Brief Pain Inventory, GODDESS DT Symptom Scale and DT Impact Scale, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 — patients treated with niro had numerically greater improvement from baseline at cycle 10 than pbo. Analyses were limited due to the small sample size. Adverse events in >50% of niro-treated patients with APC mutation were diarrhea, nausea, rash maculopapular, and fatigue; ovarian toxicity occurred in 9 of 10 of females of reproductive potential (6 resolved, 2 lost to follow-up, 1 ongoing and receiving niro). Conclusions: Improvement in PFS, ORR, tumor imaging characteristics and PROs was observed with niro compared to pbo in patients with DT harboring APC mutations. Efficacy and safety of niro in patients with APC mutations were generally consistent with findings for the overall DeFi population, suggesting that niro can provide clinically meaningful benefit to patients with progressing DT and APCmutations. Clinical trial information: NCT03785964 .
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
Mayer, L, Poon, Michelle, Ivanescu, Cristina, Chaudhry, Aafia, Ambati, Srikanth, Harnett, James , Kamat, Siddhesh , Investigators, ELM-2, Villasboas, José C. , Tessoulin, Benoit , Cho, Seok‐Goo , Taszner, Michał , Novelli, Silvana , Luminari, Stefano , Merli, Michele , Ubieto, Ana Jiménez , Tucker, David , Walewski, Jan , Mohamed, Hesham , Kim, Tae Min , Investigators, ELM-2

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e19057-e19057

10.1200/jco.2024.42.16_suppl.e19057 Get It

e19057 Background: In ELM-2 (NCT03888105), a Ph 2, single arm, open label trial, odronextamab demonstrated robust efficacy, generally manageable safety, and overall maintenance of patient-reported outcomes (PROs) in R/R FL pts (Villasboas et al. ASH 2023). In FL, pts with disease progression within 2 yrs of frontline chemoimmunotherapy (POD24) are hard to treat with poor clinical outcomes, representing an unmet need. We report PROs by POD24 status in pts with Grade 1–3a R/R FL from ELM-2. Methods: Pts received IV odronextamab in 21-day cycles (C): 80 mg QW in C1–4, with C1 dose step up to mitigate cytokine release syndrome, then 160 mg Q2W (Q4W if complete response ≥9 mo) until progression. PROs were collected at baseline (BL), Wks 2–4, 10, then Q8W in Yr 1, and Q12W in Yr 2. Post-hoc POD24 subgroup analyses were performed on six EORTC QLQ-C30 scales, the EQ-5D-3L VAS, and FACT-Lym LymS. Estimated mean change from BL (CFB) was analyzed using mixed models for repeated measures (MMRM) through Wk 42 (≥10 pts at last assessment). Published meaningful CFB thresholds were used to define deterioration/improvement in responder analyses. Results: By Jan 31, 2023, 140 pts with R/R FL had received odronextamab. Pts with POD24 (n=70) were younger than pts without POD24 (n=70; median age 57.5 vs 62.0 y), had fewer prior Tx lines (median 2 vs 3), and a higher proportion double refractory to anti-CD20 Ab + alkylator (53% vs 29%). Objective response rate was similar in evaluable pts with (n=63; 79%) and without (n=65; 80%) POD24. PRO questionnaire completion ranged from 52–95% through Wk 42 across groups. Descriptive analyses suggest BL PRO scores were similar by POD24 status, showing good HRQoL/functioning and low symptom burden, and were generally maintained through Wk 42 with minimal between-group differences (overlapping 95% CIs for LS mean CFB [Table]). In both groups, more pts reported PRO maintenance or improvement vs deterioration across visits, except for fatigue at Wk 10 in pts without POD24. Conclusions: In pts with heavily pretreated R/R FL, odronextamab Tx maintained HRQoL, functioning, and symptoms irrespective of POD24 status. Clinical trial information: NCT03888105 . [Table: see text]
Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer.
Hocum, Brian , Grossman, Jamie M., Appukkuttan, Sreevalsa , Babajanyan, Svetlana , Lee, Woojung , Cho, Sang Kyu , Bekaii‐Saab, Tanios , Grossman, Jamie, Yang, Min Jae , Barzi, Afsaneh

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3525-3525

10.1200/jco.2024.42.16_suppl.3525 Get It

3525 Background: Recent clinical trials support regorafenib dose optimization (ReDO), a combination therapy with trifluridine/tipiracil and bevacizumab (TAS-BEV), and fruquintinib (FRUQ) for the treatment of refractory metastatic colorectal cancer (mCRC). This study evaluated relative cost-effectiveness of ReDO, TAS-BEV, and FRUQ for mCRC from a payer perspective in the United States. Methods: A Markov model was constructed to estimate total costs and quality-adjusted life years (QALY) for each treatment. In the base case, clinical parameters were obtained from the ReDOS study for ReDO, the SUNLIGHT study for TAS-BEV, and the FRESCO study for FRUQ. Economic parameters were obtained from IBM Micromedex RED BOOK for treatment costs and from the Centers for Medicare & Medicaid Services and the Agency for Healthcare Research and Quality for health care resource use. Incremental cost-effectiveness ratio (ICER) was used to evaluate relative cost-effectiveness of treatments. Model robustness was checked with deterministic (DSA) and probabilistic sensitivity analysis (PSA). A subgroup analysis was performed in patients with and without previous use of anti-VEGF therapy, but using the FRESCO-2 study for FRUQ because OS and PFS for this subgroup was unavailable in the FRESCO study. Results: In the base case, ReDO provided a higher QALY at a lower cost than TAS-BEV and FRUQ. During the first two months following treatment initiation, TAS-BEV had a higher total cost ($67,862) than ReDO ($44,695) and FRUQ ($48,688), partly due to the cost of managing neutropenia and using concomitant granulocyte colony stimulating factors (GCSF). The base case results were robust in DSA and PSA. Most influential parameters determining relative cost-effectiveness were related to treatment cost and effectiveness. In patients with previous anti-VEGF therapy, ReDO provided a higher QALY at a lower cost (0.571 QALY; $86,694) than TAS-BEV (0.490 QALY; $148,784) and FRUQ (0.411 QALY; $101,236). In patients without previous anti-VEGF therapy, TAS-BEV had a higher QALY (0.755 vs 0.571) and a higher cost ($232,701 vs $86,694) than ReDO, resulting in an ICER of $790,988 per QALY. Conclusions: ReDO was cost-effective compared with TAS-BEV and FRUQ, regardless of previous use of anti-VEGF therapy. In the base case, ReDO had a lower treatment cost than TAS-BEV and FRUQ, especially during the first month of dose optimization. TAS-BEV had the highest total cost, partly due to the cost of managing neutropenia and GCSF use. [Table: see text]
Airway-occluding Mucus Plugs and Cause-specific Mortality in Chronic Obstructive Pulmonary Disease
Mettler, Sofia K. , Sonavane, Sushilkumar K. , Grumley, Scott , Nath, Hrudaya , Yen, Andrew , Pistenmaa, Carrie L. , Estépar, Raúl San Jośe , Díaz, Alejandro A. , San Jose Estepar, Raul , Diaz, Alejandro A , Yen, Andrew C., Nardelli, Pietro , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 21, 2024 | Volume: 209 | Issue: 12 | Pages: 1508-1510

10.1164/rccm.202401-0121le | PMID 38771048 Get It